PD-LID Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Adamas Pharma, Novartis, EMD Serono, PharmaTher, Neurolixis, Bukwang Pharma, Vistagen Therapeutics, Avanir Pharma

DelveInsight's "Parkinson's Disease Levodopa-induced Dyskinesia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Parkinson's Disease Levodopa-induced Dyskinesia, historical and forecasted epidemiology as well as the Parkinson's Disease Levodopa-induced Dyskinesia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Parkinson's Disease Levodopa-induced Dyskinesia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Parkinson's Disease Levodopa-induced Dyskinesia Market Forecast
https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Parkinson's Disease Levodopa-induced Dyskinesia Market Report:
• The PD-LID market size was valued USD 1,504 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2025, A daily dose of CPL'36, an investigational oral small molecule developed by Celon Pharma, may help alleviate symptoms of levodopa-induced dyskinesia-uncontrolled movements caused by long-term Parkinson's disease treatment-within just one week. This finding comes from a Phase 2 clinical trial (NCT05297201) evaluating CPL'36 against a placebo in 105 adults with Parkinson's disease. The study also aims to assess the safety profile of CPL'36 and its pharmacokinetics-how the drug is absorbed, distributed, metabolized, and excreted in the body.
• In October 2024, AbbVie announced that it has received FDA approval for VYALEV (foscarbidopa/foslevodopa), a treatment for motor fluctuations in adults with advanced Parkinson's disease. This marks the first 24-hour continuous subcutaneous infusion of a levodopa-based therapy.
• In 2023, the US held the largest market share for PD-LID, with a value of approximately USD 904 million, compared to the combined markets of EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
• Based on DelveInsight's estimates, Germany had the largest PD-LID market among the EU4 and the UK, with approximately USD 134 million in 2023, followed by France at around USD 112 million. Spain had the smallest market share, accounting for about USD 83 million in the same year.
• The total PD-LID market size in Japan was approximately USD 89 million in 2023 and is projected to grow by 2034.
• The total diagnosed prevalent cases of PD-LID across the 7MM were estimated to be around 597 thousand in 2023, with an expected increase during the forecast period (2024-2034).
• According to the analysis, in 2023, the US represented approximately 49% of the total diagnosed prevalent cases of PD-LID, EU4 and the UK accounted for nearly 43%, and Japan made up around 8%.
• In 2023, the US saw the highest prevalence of peak-dose dyskinesia in PD-LID, with approximately 236 thousand cases, followed by off-period dystonia with around 89 thousand cases. Diphasic dyskinesia had the lowest prevalence, with roughly 59 thousand cases.
• According to the epidemiology model for PD-LID in EU4 and the UK, Germany had the highest diagnosed prevalent population of PD-LID, with around 67 thousand cases, followed by France with approximately 56 thousand diagnosed cases in 2023.
• Key PD-LID Companies: PharmaTher, Neurolixis, Bukwang Pharmaceutical, Vistagen Therapeutics, Adamas Pharmaceuticals, Inc., Novartis, EMD Serono, Avanir Pharmaceuticals, UCB Pharma, and others
• Key PD-LID Therapies: KETARX(ketami ne), NLX-112/F13640(befiradol), JM-010, AV-101, ADS-5102, AFQ056, Sarizotan HCl, AVP-923-45, AFQ056, Levetiracetam, and others
• The Parkinson's Disease Levodopa-induced Dyskinesia epidemiology based on type-specific cases analyzed that there are three types of PD-LID: peak-dose dyskinesia, off period dystonia, and diphasic dyskinesia, among which peak-dose dyskinesia accounted for the highest number of cases, whereas diphasic dyskinesia for least during the forecast period.
• The Parkinson's Disease Levodopa-induced Dyskinesia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Parkinson's Disease Levodopa-induced Dyskinesia pipeline products will significantly revolutionize the Parkinson's Disease Levodopa-induced Dyskinesia market dynamics.

PD-LID Overview
Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID) refers to involuntary, erratic, and often excessive movements that develop as a side effect of long-term use of levodopa, a common medication used to manage the symptoms of Parkinson's disease. Levodopa is considered the most effective treatment for reducing the motor symptoms of Parkinson's disease, such as tremors, rigidity, and bradykinesia (slowness of movement). However, over time, many patients develop dyskinesia as a complication of the treatment.

Get a Free sample for the Parkinson's Disease Levodopa-induced Dyskinesia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology Segmentation:
The Parkinson's Disease Levodopa-induced Dyskinesia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Parkinson's Disease Levodopa-induced Dyskinesia
• Prevalent Cases of Parkinson's Disease Levodopa-induced Dyskinesia by severity
• Gender-specific Prevalence of Parkinson's Disease Levodopa-induced Dyskinesia
• Diagnosed Cases of Episodic and Chronic Parkinson's Disease Levodopa-induced Dyskinesia

Download the report to understand which factors are driving Parkinson's Disease Levodopa-induced Dyskinesia epidemiology trends @ Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology Forecast
https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

PD-LID Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson's Disease Levodopa-induced Dyskinesia market or expected to get launched during the study period. The analysis covers Parkinson's Disease Levodopa-induced Dyskinesia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Parkinson's Disease Levodopa-induced Dyskinesia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Parkinson's Disease Levodopa-induced Dyskinesia Therapies and Key Companies
• KETARX(ketami ne): PharmaTher
• NLX-112/F13640(befiradol): Neurolixis
• JM-010: Bukwang Pharmaceutical
• AV-101: Vistagen Therapeutics
• ADS-5102: Adamas Pharmaceuticals, Inc.
• AFQ056: Novartis
• Sarizotan HCl: EMD Serono
• AVP-923-45: Avanir Pharmaceuticals
• AFQ056: Novartis
• Levetiracetam: UCB Pharma

Discover more about therapies set to grab major Parkinson's Disease Levodopa-induced Dyskinesia market share @ Parkinson's Disease Levodopa-induced Dyskinesia Treatment Landscape
https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

PD-LID Market Drivers
• The concept of 'drug-repurposing' has been used in drug development for LID for many years, for instance, amantadine was initially licensed for viral infections, and clinical observation noted improved symptoms in PD subjects using the drug for influenza.
• The constant researches on novel AI-driven computational approaches and improvements in formulating long-acting LDOPA preparations or infusion systems offer means to drive drug discovery, which may further lower the incidence of LID.

PD-LID Market Barriers
• The increasing prevalence of PD in the geriatric population offers a potential market to the key pharma players, as ~50% of PD patients on L-DOPA experience LID.
• Improvements in the measurement of LID may emerge from technological advances, for instance, a wearable device easily worn by the patient at home that provides a measure oflimb/trunk movement that correlates with LID level.

Scope of the Parkinson's Disease Levodopa-induced Dyskinesia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Parkinson's Disease Levodopa-induced Dyskinesia Companies: PharmaTher, Neurolixis, Bukwang Pharmaceutical, Vistagen Therapeutics, Adamas Pharmaceuticals, Inc., Novartis, EMD Serono, Avanir Pharmaceuticals, UCB Pharma, and others
• Key Parkinson's Disease Levodopa-induced Dyskinesia Therapies: KETARX(ketami ne), NLX-112/F13640(befiradol), JM-010, AV-101, ADS-5102, AFQ056, Sarizotan HCl, AVP-923-45, AFQ056, Levetiracetam, and others
• Parkinson's Disease Levodopa-induced Dyskinesia Therapeutic Assessment: Parkinson's Disease Levodopa-induced Dyskinesia current marketed and Parkinson's Disease Levodopa-induced Dyskinesia emerging therapies
• Parkinson's Disease Levodopa-induced Dyskinesia Market Dynamics: Parkinson's Disease Levodopa-induced Dyskinesia market drivers and Parkinson's Disease Levodopa-induced Dyskinesia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Parkinson's Disease Levodopa-induced Dyskinesia Unmet Needs, KOL's views, Analyst's views, Parkinson's Disease Levodopa-induced Dyskinesia Market Access and Reimbursement

To know more about Parkinson's Disease Levodopa-induced Dyskinesia companies working in the treatment market, visit @ Parkinson's Disease Levodopa-induced Dyskinesia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Parkinson's Disease Levodopa-induced Dyskinesia Market Report Introduction
2. Executive Summary for Parkinson's Disease Levodopa-induced Dyskinesia
3. SWOT analysis of Parkinson's Disease Levodopa-induced Dyskinesia
4. Parkinson's Disease Levodopa-induced Dyskinesia Patient Share (%) Overview at a Glance
5. Parkinson's Disease Levodopa-induced Dyskinesia Market Overview at a Glance
6. Parkinson's Disease Levodopa-induced Dyskinesia Disease Background and Overview
7. Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology and Patient Population
8. Country-Specific Patient Population of Parkinson's Disease Levodopa-induced Dyskinesia
9. Parkinson's Disease Levodopa-induced Dyskinesia Current Treatment and Medical Practices
10. Parkinson's Disease Levodopa-induced Dyskinesia Unmet Needs
11. Parkinson's Disease Levodopa-induced Dyskinesia Emerging Therapies
12. Parkinson's Disease Levodopa-induced Dyskinesia Market Outlook
13. Country-Wise Parkinson's Disease Levodopa-induced Dyskinesia Market Analysis (2020-2034)
14. Parkinson's Disease Levodopa-induced Dyskinesia Market Access and Reimbursement of Therapies
15. Parkinson's Disease Levodopa-induced Dyskinesia Market Drivers
16. Parkinson's Disease Levodopa-induced Dyskinesia Market Barriers
17. Parkinson's Disease Levodopa-induced Dyskinesia Appendix
18. Parkinson's Disease Levodopa-induced Dyskinesia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-pd-lid-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Parkinson's Disease Levodopa-induced Dyskinesia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market
• Peritoneal Dialysis Equipment Market: https://www.delveinsight.com/report-store/peritoneal-dialysis-equipment-market
• Drug-eluting Stents Market Market: https://www.delveinsight.com/report-store/drug-eluting-stents-market
• Sinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Pd-1 & Pdl1 Market: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Cervical Dysplasia Market: https://www.delveinsight.com/report-store/cervical-dysplasia-market-insights

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.